Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology (NASDAQ: PBYI) announced the approval of an inducement restricted stock unit award of 5,625 shares to a new non-executive employee. The award, granted under the company's 2017 Employment Inducement Incentive Award Plan, will vest over three years, with one-third vesting after the first year and one-sixth every six months thereafter, starting from November 1, 2024. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Puma Biotechnology (NASDAQ: PBYI) ha annunciato l'approvazione di un premio in azioni riservate in forma di unità di stock di indennità di 5.625 azioni a un nuovo dipendente non esecutivo. Il premio, concesso nell'ambito del piano di incentivi per l'occupazione del 2017 dell'azienda, maturerà nell'arco di tre anni, con un terzo che matura dopo il primo anno e un sesto ogni sei mesi successivamente, a partire dal 1° novembre 2024. Questa assegnazione è stata effettuata in conformità con la Regola di quotazione Nasdaq 5635(c)(4) come indennità per l'occupazione.
Puma Biotechnology (NASDAQ: PBYI) anunció la aprobación de un premio de unidad de acciones restringidas de inducción de 5,625 acciones para un nuevo empleado no ejecutivo. El premio, otorgado bajo el Plan de Incentivos por Inducción al Empleo de 2017 de la compañía, se consolidará en un periodo de tres años, con un tercio consolidándose después del primer año y un sexto cada seis meses a partir de entonces, comenzando el 1 de noviembre de 2024. Esta concesión se realizó de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4) como un incentivo para el empleo.
푸마 생명공학 (NASDAQ: PBYI)는 새로운 비즈니스 직원에게 5,625주에 해당하는 유도 제한 주식 단위 보상을 승인했다고 발표했습니다. 이 보상은 회사의 2017년 고용 유도 인센티브 보상 계획에 따라 주어지며, 3년에 걸쳐 분배됩니다. 첫 해 후에 1/3이 분배되고 그 이후로는 6개월마다 1/6씩 분배됩니다. 이 분배는 2024년 11월 1일부터 시작됩니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유도를 위해 이루어졌습니다.
Puma Biotechnology (NASDAQ: PBYI) a annoncé l'approbation d'une attribution d'unités d'actions réservées de 5 625 actions à un nouvel employé non exécutif. L'attribution, accordée dans le cadre du Plan d'Incitation à l'Emploi de 2017 de l'entreprise, sera acquise sur une période de trois ans, avec un tiers acquis après la première année et un sixième tous les six mois par la suite, à compter du 1er novembre 2024. Ce don a été fait conformément à la règle de cotation Nasdaq 5635(c)(4) comme incitation à l'emploi.
Puma Biotechnology (NASDAQ: PBYI) hat die Genehmigung einer Induktionsbeschränkten Aktieneinheitenauszeichnung von 5.625 Aktien für einen neuen nicht-executive Mitarbeiter bekannt gegeben. Die Auszeichnung, die im Rahmen des Beschäftigungsinduktions-Incentive-Programms 2017 des Unternehmens gewährt wurde, wird über drei Jahre hinweg fällig, wobei ein Drittel nach dem ersten Jahr und ein Sechstel alle sechs Monate danach fällig wird, beginnend am 1. November 2024. Diese Vergabe wurde gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für die Beschäftigung vorgenommen.
- None.
- None.
The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, November 1, 2024, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105277353/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Source: Puma Biotechnology, Inc.
FAQ
How many shares were granted in Puma Biotechnology's (PBYI) latest inducement award?
What is the vesting schedule for Puma Biotechnology's (PBYI) November 2024 inducement award?
Under which plan did Puma Biotechnology (PBYI) grant its November 2024 inducement award?
